{"id":1050,"date":"2021-05-27T11:39:29","date_gmt":"2021-05-27T11:39:29","guid":{"rendered":"https:\/\/nclinnovations.org\/covid19monitor\/?p=1050"},"modified":"2021-05-27T11:39:29","modified_gmt":"2021-05-27T11:39:29","slug":"17-may-2021-bamlanivimab-94-4-showed-improvement-in-24-72-hrs","status":"publish","type":"post","link":"https:\/\/nclinnovations.org\/covid19monitor\/17-may-2021-bamlanivimab-94-4-showed-improvement-in-24-72-hrs\/","title":{"rendered":"(17 May 2021) Bamlanivimab- 94.4 % showed improvement in 24-72 hrs"},"content":{"rendered":"<div class=\"boldgrid-section\">\n<div class=\"container\">\n<div class=\"row\">\n<div class=\"col-md-12 col-xs-12 col-sm-12\">\n<p class=\"\">Bamlanivimab Use in a Military Treatment Facility<\/p>\n<p>https:\/\/doi.org\/10.1093\/milmed\/usab188<\/p>\n<p class=\"\">Of the COVID-19 patients who were given the option of a bamlanivimab infusion, 40 accepted and 6 did not (40\/46, 86.9%). Thirty-six of 40 patients in the treatment group were contacted within 72 hours. ED\/hospitalization information was available for all 46 patients. In the treatment group, 94.4% (34\/36) reported global improvement. Three of 40 (7.5%) patients in the treatment group required inpatient admission, and 2 of 40 patients (5%) required ED evaluation within 30 days of infusion. Therefore, 5 of 40 (12.5%) patients required evaluation shortly after infusion, while 2 of 6 (33.3%) patients who declined treatment required hospital evaluation or admission related to COVID-19 within 30 days of infusion (P = .15).&nbsp; Global improvement of symptoms within 24 to 72 hours of infusion was reported by 94.4% of patients receiving bamlanivimab; however, statistical significance could not be determined due to the small sample size and lack of placebo group due to study design.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Bamlanivimab Use in a Military Treatment Facility https:\/\/doi.org\/10.1093\/milmed\/usab188 Of the COVID-19 patients who were given the option of a bamlanivimab infusion, 40 accepted and 6 did not (40\/46, 86.9%). Thirty-six of 40 patients in the treatment group were contacted within&hellip; <span class=\"read-more-span\"><a href=\"https:\/\/nclinnovations.org\/covid19monitor\/17-may-2021-bamlanivimab-94-4-showed-improvement-in-24-72-hrs\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;(17 May 2021) Bamlanivimab- 94.4 % showed improvement in 24-72 hrs&#8221;<\/span> <span class=\"genericon genericon-next\"><\/span><\/a><\/span><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"bgseo_title":"","bgseo_description":"","bgseo_robots_index":"index","bgseo_robots_follow":"follow"},"categories":[99,4],"tags":[100],"_links":{"self":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/1050"}],"collection":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/comments?post=1050"}],"version-history":[{"count":1,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/1050\/revisions"}],"predecessor-version":[{"id":1051,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/1050\/revisions\/1051"}],"wp:attachment":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/media?parent=1050"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/categories?post=1050"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/tags?post=1050"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}